<DOC>
	<DOCNO>NCT00396266</DOCNO>
	<brief_summary>This study evaluate safety efficacy plerixafor give addition granulocyte-colony stimulate factor ( G-CSF ) collection peripheral blood stem cell ( PBSCs ) autologous transplantation patient non-Hodgkin 's lymphoma ( NHL ) multiple myeloma ( MM ) . Efficacy outcomes include evaluation fold increase circulate CD34+ cell first plerixafor injection 10-11 hour post plerixafor ( apheresis ) assessment successful polymorphonuclear leukocyte ( PMN ) engraftment transplantation . Data protocol assist determination dose schedule future study .</brief_summary>
	<brief_title>AMD3100 ( Plerixafor ) Given NHL MM Patients Increase Number PBSCs When Given Mobilizing Regimen G-CSF</brief_title>
	<detailed_description>Participants NHL MM undergone prior cyto-reductive chemotherapy , autologously transplant , meet inclusion/exclusion criterion eligible enter study . The change standard care addition plerixafor granulocyte colony-stimulating factor ( G-CSF ) mobilization regimen day prior apheresis . Participants undergo mobilization G-CSF ( 10 mcg/kg day ) receive plerixafor ( 240 mcg/kg ) even prior apheresis . Participants undergo apheresis 5 consecutive day order collect target number CD34+ stem cell ( ≥ 5*10^6 CD34+ cells/kg either single tandem transplant ) . After apheresis , participant treat high-dose chemotherapy preparation transplantation . Participants transplant cell obtain G-CSF plerixafor mobilization regimen . The increase CD34+ cell peripheral blood time plerixafor dose prior apheresis number CD34+ cell apheresis product measure . Success transplantation ( ) evaluate time engraftment polymorphonuclear leukocyte ( PMN ) . A subpopulation pharmacokinetic pharmacodynamic analysis do . This study previously post AnorMED , Inc . In November 2006 , AnorMED , Inc. acquire Genzyme Corporation . Genzyme Corporation sponsor trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Diagnosis nonHodgkin 's lymphoma ( NHL ) multiple myoloma ( MM ) eligible autologous transplantation No 3 prior regimen chemotherapy More 4 week since last cycle chemotherapy . Patient recover acute toxic effect prior chemotherapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 White blood cell ( WBC ) count &gt; 3.0*10^9/L Absolute polymorphonuclear cell ( PMN ) count &gt; 1.5*10^9/L Platelet ( PLT ) count &gt; 100*10^9/L Serum creatinine &lt; =2.2 mg/dL Serum glutamic oxaloacetic transaminase ( SGOT ) , serum glutamic pyruvic transaminase ( SGPT ) total bilirubin &lt; 2 x upper limit normal ( ULN ) Left ventricle ejection fraction &gt; 45 % normal echocardiogram multiplegated acquisition ( MUGA ) scan Forced expiratory volume lung first second ( FEV1 ) &gt; 60 % predict diffusing capacity lung carbon monoxide ( DLCO ) &gt; 45 % predict Negative human immunodeficiency virus ( HIV ) type 1 Women child bear potential agree use approve form contraception . • Patients fail previous collection Brain metastasis carcinomatous meningitis History ventricular arrhythmias A comorbid condition , view investigator , render patient high risk treatment complication A residual acute medical condition result prior chemotherapy Acute infection Fever ( temp &gt; 38°C/100.4°F ) Patients whose actual body weight exceeds 150 % ideal body weight History paresthesia ( least Grade 2 ) Patients previously receive experimental therapy within 4 week enrol study currently enrol another experimental study mobilization period Positive pregnancy test female patient Lactating female Patients childbearing potential unwilling implement adequate birth control . Patients deterioration clinical status laboratory parameter time enrolment transplant ( long meet entry criterion ) may remove study discretion treat physician , principal investigator , sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>stem cell mobilization</keyword>
	<keyword>AMD3100</keyword>
	<keyword>autologous transplantation</keyword>
</DOC>